Castres

This research aims to find out how common cardiac amyloidosis is among older adults aged 80 years and above who have been hospitalized for heart failure and show thickening of the hearts left ventricle. The study is observational and conducted across multiple geriatric and cardiology centers. It focuses on patients who have experienced heart failure with specific heart muscle changes seen on echocardiography. Participants will be recruited over 24 months and followed for 12 months. At the start, researchers will collect medical history, demographic information, clinical data, frailty status, biological and genetic tests, and echocardiogram results. Bone scans using specific tracers will be performed during or after hospital stays to check for heart muscle involvement. Follow-up will include phone calls every three months to track hospitalizations, care facility admissions, and survival. During the study, participants will have regular assessments including frailty scales, cognitive tests, and questionnaires related to neuropathic pain and independence in daily activities. Researchers will evaluate bone scan results to detect amyloidosis and measure other health and functional outcomes. The study aims to provide a clearer picture of cardiac amyloidosis prevalence and patient condition over one year.

Researchers are studying the World Health Organizations Integrated Care for Older People ICOPE program to see if it helps prevent age-related decline in older adults. This study compares the comprehensive ICOPE program with usual care from primary doctors. The goal is to determine if regular screening, personalized care plans, and follow-up can better maintain functions like mobility, cognition, and nutrition in people aged 65 and older living at home. The trial randomly assigns participants to either receive the full ICOPE program or usual care. The ICOPE program includes screening every six months using a digital tool, a thorough assessment of six key functions, a personalized intervention plan, and ongoing follow-up, including phone calls and annual visits over 60 months. After an initial 36-month intervention, all participants receive the ICOPE program during a 24-month extension phase. Participants have annual visits at 12, 24, 36, 48, and 60 months, during which a research nurse collects data while unaware of which group they are in. Phone calls occur between visits to support the care plan and gather information about life events. The primary outcome measured is functional decline at 36 months. The study runs until 2031, with continuous monitoring of participants health and program adherence.

Researchers are evaluating the device RGn600 for treating adults aged 55 to 85 with mild-to-moderate Alzheimers disease. This study aims to demonstrate how RGn600, which combines PhotoBioModulation light therapy using lasers and LEDs and Static Magnetic Stimulation, might reduce brain-gut axis inflammation linked to Alzheimers. The trial is randomized and controlled, involving 108 patients in France over a 52-week period. Participants will be randomly assigned to receive either the active RGn600 device or a sham inactive device. Treatments occur on-site during 20-minute sessions, with five sessions per week for the first 8 weeks, three sessions per week from weeks 9 to 16, and two sessions per week from weeks 17 to 26. After this treatment period, participants will continue to be followed for safety and effects up to week 52. Throughout the study, patients will attend four main visits at the start Day 0, week 8, week 26, and week 52. During these visits, researchers will assess cognition and autonomy using neurological and neuropsychological tests, quality of life through questionnaires with caregiver assistance, and safety by monitoring adverse events and conducting blood tests. Additionally, biological samples like blood, fecal, and saliva samples will be collected from participants at the Toulouse site to support further research on Alzheimers markers and inflammation.

Researchers are evaluating the impact on quality of life and economic outcomes of combining a scheduled consultation with a hospital clinical pharmacist and electronic patient-reported outcomes ePRO monitoring for patients undergoing oral cancer therapies. The study focuses on patients with metastatic or locally advanced cancer starting oral therapy, addressing issues like drug interactions, side effects, and the gap between patient and physician reporting of symptoms. Improving detection of drug interactions and monitoring toxicities aims to enhance patient care and treatment adherence. Participants are randomly assigned to either a group receiving proactive medication assessment with the hospital pharmacist plus follow-up using the THESS electronic monitoring system or to standard care without these interventions. The study involves scheduled consultations to detect potential drug interactions and inform patients about their treatments, alongside weekly symptom reporting via the THESS app. This approach integrates therapeutic follow-up and clinical information collection to better manage treatment toxicities. During the study, patients will be closely monitored for changes in quality of life, toxicity levels, treatment adherence, and patient satisfaction over up to 18 months. Assessments include patient-reported symptoms, medication adherence, prescription changes, and economic evaluations such as cost of care and budget impact analysis. Data collection occurs regularly at intervals up to 18 months, allowing researchers to measure time until a 5-point decrease in quality of life and other health outcomes, ensuring comprehensive monitoring throughout the study period.